Overcoming cellular senescence in human cancer pathogenesis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Elevation of p16, the CDKN2/p16 tumor suppressor gene (TSG) product, occurs at senescence in normal human uroepithelial cells (HUC). Immortal HUCs and bladder cancer cell lines show either alteration of p16 or pRb, the product of the retinoblastoma (RB) TSG. In addition, many human cancers show p16 or pRb alteration along with other genetic alterations that we associated with immortalization, including +20q and −3p. These observations led us to hypothesize that p16 elevation plays a critical role in senescence cell cycle arrest and that overcoming this block is an important step in tumorigenesis in vivo, as well as immortalization in vitro. Using a novel approach, we tested these hypotheses in the present study by examining p16 and pRb status in primary culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represented both superficial bladder tumors and invasive bladder cancers. We demonstrated that all superficial TCCs showed elevated p16 after limited passage in vitro and then senesced, like normal HUCs. In contrast, all muscle invasive TCCs contained either a p16 or a pRb alteration at P0 and all spontaneously bypassed senescence (P = 0.001). Comparative genomic hybridization (CGH) was used to identify regions of chromosome loss or gain in all TCC samples. The application of a statistical model to the CGH data showed a high probability of elevated alteration rates of +20q11−q12 (0.99) and +8p22−pter (0.94) in the immortal muscle invasive TCCs, and of −9q (0.99) in the superficial TCCs. Three myoinvasive TCCs lost 3p13−p14. In this study, four of six myoinvasive TCCs also showed TP53 mutation that associated well with genome instability (P = 0.001), as previously hypothesized. Notably,TP53 mutation, which has been used as a marker of tumor progression in many human cancers, was less significant in associating with progression in this study (P = 0.04) than was p16 or pRb alteration (P = 0.001). Thus, these data support a new model in which overcoming senescence plays a critical role in human cancer pathogenesis and requires at least two genetic changes that occur in several combinations that can include either p16 or pRb loss and at least one additional alteration, such as +20q11−q12, −3p13−p14, or −8p21−pter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 3×
“Assessment of b-galactosidase activity b-Galactosidase activity was used as a marker for cellular se- nescence (Dimri et al. 1995).”
MethodOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Notably, our observation that p16 elevation occurs at senescence in human epithelial cells has been confirmed (Serrano et al. 1997).”
BackgroundA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Furthermore, a higher percentage of these mutations were observed in TCC cell lines than in uncultured tumors (Kamb et al. 1994).”
BackgroundMeyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Cited by
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.-Y., & Campisi, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211053698 · Cited by 1,730
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
Esteller, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205600 · Cited by 1,233
Cancer and ageing: rival demons?
Campisi, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1073 · Cited by 512
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota, M., Ohe-Toyota, M., Ahuja, N., & Issa, J.-P. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.710 · Cited by 473
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
Profiling early head and neck cancer
Hunter, K. D., Parkinson, E. K., & Harrison, P. R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1549 · Cited by 437
Regulation of cellular senescence by p53
Itahana, K., Dimri, G., & Campisi, J. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02228.x · Cited by 365
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
“In accordance with the view that oncogenic signalling provokes activation of failsafe responses prior to their mutational inactivation, upregulation of mediators such as INK4A or p53 can be detected in precancerous lesions or early-stage malignancie”
BackgroundCancer and aging: a model for the cancer promoting effects of the aging stroma
Krtolica, A., & Campisi, J. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00053-5 · Cited by 295
Wong, N., Lai, P., Lee, S.-W., Fan, S., Pang, E., Liew, C.-T., Sheng, Z., Lau, J. W.-Y., & Johnson, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65248-0 · Cited by 275
From cells to organisms: can we learn about aging from cells in culture?
Campisi, J. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00230-8 · Cited by 267
Genetic and Epigenetic Changes in Human Epithelial Cells Immortalized by Telomerase
Farwell, D. G., Shera, K. A., Koop, J. I., Bonnet, G. A., Matthews, C. P., Reuther, G. W., Coltrera, M. D., McDougall, J. K., & Klingelhutz, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65025-0 · Cited by 196
Jones, C. J., Kipling, D., Morris, M., Hepburn, P., Skinner, J., Bounacer, A., Wyllie, F. S., Ivan, M., Bartek, J., Wynford-Thomas, D., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5690-5699.2000 · Cited by 89
“Such a clock also seems to operate in controlling physiological (growth factor induced) proliferative life span in a variety of situations, including primary fibroblasts in rodents (54) and, moreover, several specific types of human epithelium, including mammary epithelial cells (20, 34), keratinocytes (34) and uroepi…”
BackgroundReplicative senescence revisited.
Marcotte, R., & Wang, E. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.7.b257 · Cited by 86
Nickoloff, B. J. (2001) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2001.280201.x · Cited by 78
Metadata
- Authors
- Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., Newton, M. A., Waldman, F. M., & Reznikoff, C. A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1998-01-15
- Volume
- 12
- Issue
- 2
- Pages
- 163-174
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2112397570
- Cited by
- 152
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.